These clinical data suggest that tumors from lung cancer patients with poor survival are characterized by a distinct immunosuppressive TME with a high level of tumor-infiltrating Rab37+/PD-1+/TIM3+/CD8+ T cells. This evidence concerns the gene CD8A and lung carcinoma.